Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Stock Market Crash News Today Live Updates: Nifty Falls Near 23,200, Sensex Declines Over 400 Points; Wockhardt, Schneider Electric Falls 5%
Sectoral indices were mixed in early trade, with Nifty IT rising 2.18% and Nifty Metal gaining 0.13%. On the flipside, Nifty Financial Services fell 1.07%, while Nifty Pharma declined 1.03%.
Zaynich's blockbuster potential lifts Wockhardt's long-term outlook
Wockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of net losses. The drug, targeting multidrug-resistant bacteria, has a projected peak sales of $1.5 billion, potentially transforming the company's financial outlook. Investors have responded positively, with the stock surging on the news.
Wockhardt’s new drug, India’s second to get US nod, now eyes commercial success
The nod for Zaynich—an antibiotic for treatment of complicated UTI—vindicates chairman and founder Habil Khorakiwala’s bet on antibiotic discovery and development, even as Big Pharma companies in developed economies stopped such research in favour of more lucrative drugs.
If you have the patience, you can achieve innovation milestones, says Wockhardt chairman Habil Khorakiwala
Wockhardt Hospitals is set to launch its antibiotic Zaynich in the US. Zahabiya Khorakiwala will lead US operations. The drug is expected to generate $1.5-2 billion in peak annual sales within 4-6 years. Wockhardt aims for a 20% share of the AMR market. The company is also developing new antibiotics for its pipeline.
Ahead of Market: 10 things that will decide stock market action on Tuesday
Benchmark indices Sensex and Nifty fell for a fourth straight session amid elevated crude oil prices, geopolitical tensions and persistent selling pressure. Market breadth remained weak, technical indicators turned bearish, while select stocks including Wockhardt and NMDC Steel attracted buying interest and hit fresh highs.
Wockhardt among 8 stocks hit 52-week highs, rally up to 55% in a month
Buy, Sell Or Hold: Suzlon, Wockhardt, Natco Pharma, JSW Infra, HDFC Bank, Zaggle — Ask Profit
Buy Sell Hold
Wockhardt Ltd spurts 8.35%, gains for fifth straight session
Wockhardt Ltd is quoting at Rs 2201.1, up 8.35% on the day as on 12:44 IST on the NSE. The stock is up 50.14% in last one year as compared to a 4.86% jump in NIFTY and a 13.48% jump in the Nifty Pharma.
Wockhardt shares jump 45% in five sessions after USFDA approval for key breakthrough drug
The USFDA approved Wockhardt's antibiotic WCK 5222, marketed under the brand name Zaynich, for the treatment of complicated urinary tract infections (cUTIs).
Four pharma stocks that should be on your radar today
Wockhardt received USFDA approval for its antibiotic Zaynich, a drug the company believes could generate annual sales of $1 billion to $2 billion globally. Lupin secured USFDA approval for the generic version of Sutab and will enjoy 180 days of marketing exclusivity in the US market.
Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check details
Wockhardt's shares surged 19% after the U.S. FDA approved ZAYNICH, a novel intravenous antibiotic for complicated urinary tract infections. The drug, combining cefepime and zidebactam, demonstrated superior efficacy over meropenem in a Phase 3 trial. This approval addresses the growing challenge of antimicrobial resistance.
US FDA Approval For Zaynich Puts Wockhardt's Innovation Bet To The Test
Zaynich, approved for complicated urinary tract infections and pyelonephritis, is aimed at treating infections caused by drug-resistant bacteria — an area where doctors globally are facing shrinking treatment options as antimicrobial resistance rises.